Unlocking the Full Potential of RNA Therapies: Why Delivery is the Game-Changer

By Susan Najjar

​RNA therapies have surged into the spotlight in recent years, thanks to their role in the rapid development of COVID-19 vaccines. But according to Nigel Theobald, CEO of N4 Pharma, the real story is only just beginning.
​
In a recent interview with Life Sciences Decoded, Nigel broke down the fundamentals of RNA therapeutics and explained why the next major leap in this field depends not on the RNA itself—but on how it's delivered.

What Are RNA Therapeutics, and Why Do They Matter?
Nigel offers a down-to-earth explanation: “RNA, along with DNA, are nucleic acids—core components of all human life. RNA acts as a messenger, translating DNA's genetic instructions into proteins that the body needs to function.”

But in diseases like cancer, inflammatory bowel disease (IBD), or viral infections, the body may produce too much or too little of a critical protein. RNA therapies aim to correct that imbalance. They either:

• Turn protein production on (using messenger RNA or mRNA), or
• Turn it off (using small interfering RNA or siRNA).

The potential? Tremendous. RNA can target previously "undruggable" diseases, offers a faster path to discovery than traditional small molecules or antibodies, and can even be tailored for personalized medicine.

The Catch: Delivery is Everything
Despite the promise, one glaring challenge remains: getting RNA into the right cells safely and effectively.

“RNA is fragile,” Nigel explains. “The body immediately tries to break it down. Even if you protect it, you still face barriers like the cell membrane. Both RNA and the cell surface carry negative charges—they repel each other. Most delivery systems only succeed by overwhelming the body with a large dose, hoping a small fraction gets through.”

And even if RNA enters a cell, it can get stuck in the endosome and never reach the cytoplasm where it’s needed. Add to that the fact that today’s systems tend to deliver RNA indiscriminately across the body—most ending up in the liver—and you have a delivery bottleneck limiting the potential of RNA therapies.

Enter Nuvec®: A Novel Silica-Based Delivery System
To solve this, N4 Pharma developed Nuvec®, a silica nanoparticle with a unique “spiky” structure that mimics grass burrs sticking to your socks.
This structure:

• Physically traps RNA to protect it from degradation,
• Facilitates cellular uptake and endosomal escape (a major bottleneck),
• Supports oral delivery, and
• Enables multiple RNA payloads to be loaded on a single particle.

​“Existing systems like lipids or viral vectors can only deliver one thing at a time, and they’re expensive and complex to make,” Nigel explains. “Our silica particles are easy to manufacture, scalable, and low-cost. We’re not just solving delivery—we’re expanding what delivery can do.”

From Science to Application: A New Hope for IBD
N4 Pharma’s first clinical candidate--N4-101—is being developed for ulcerative colitis, a serious form of inflammatory bowel disease. What makes it stand out?
​

• It's orally delivered.
• It targets macrophage cells in the gut using a mannose ligand.
• It combines two payloads:
  • An siRNA that knocks down TNF-α, a key inflammatory protein.
  • An mRNA that boosts IL-10, a natural anti-inflammatory agent.

In preclinical studies, N4-101 demonstrated:
​

• Complete knockdown of TNF-α,
• Significantly elevated IL-10 levels,
• Improved colon length, and
• Sustained effects lasting over two weeks.

All with a capsule designed to release at the ideal pH level—directly in the upper GI tract.

A Future Beyond Injections
So, are injections the only route for RNA therapies?

“Not anymore,” Nigel says. “They only dominate because of today’s limitations. But with novel delivery systems like Nuvec, we’re proving that oral and even topical applications are possible.”

​And that opens the door to a future where RNA therapies could be taken as easily as antibiotics—targeting everything from rare genetic diseases to common chronic conditions.

The Bottom Line: RNA Therapies Need Better Delivery to Realize Their Promise
The science behind RNA is sound. The potential is vast. But as Nigel puts it, “RNA therapeutics are only as effective as the systems that deliver them.” N4 Pharma’s Nuvec system is tackling this head-on—with a delivery platform that is protective, scalable, customizable, and most importantly, patient-friendly.

As the industry shifts from promise to practical application, innovations in delivery may well be the key that unlocks RNA’s full therapeutic power.